Fig. 6
From: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy
Oxaliplatin resistance mediated by IL-11 can be overcome by blocking the IL-11 pathway. a: IL-11 partially rescued the colon cancer cells treated with oxaliplatin. Human colon cancer cells (DLD-1, HCT-15, and HCT-116) were starved in serum-free medium in 96-well plates at a density of 3000 cells per well for 24 h. The next day, the cells were pre-treated with 10 μM oxaliplatin for 2 h followed by 50 ng/ml IL-11 stimulation. After 24 h (DLD-1 cells) or 48 h (HCT-15 and HCT-116 cells) of treatment, cell viability was measured by MTT assay. b: The neutralized IL-11 Ab can enhance the efficacy of oxaliplatin. Human colon cancer cells (DLD-1, HCT-15, and HCT-116) were starved in serum-free medium in 96-well plates at a density of 3000 cells per well for 24 h. Neutralized IL-11 antibodies at 1000 ng/ml (DLD-1 and HCT-15 cells) or 50 ng/ml (HCT-116 cells) were added alone or with 1 μM oxaliplatin, which was added 4 h later. After 48-h treatment, cell viability was measured by MTT assay. (**, p < 0.01; ***, p < 0.001)